Table A5.
Classification performance of plasma polyamines in distinguishing serous and non-serous cases from controls in the Test Set.
| All Serous Cases (n = 91) vs. Healthy Controls (n = 71) | All Serous Cases (n = 91) vs. Subjects with Benign Cysts (n = 72) | |||||||||
| Metabolite | AUC | 95% CI | p † | Sens @ 95% Spec | Spec @ 95% Sens | AUC | 95% CI | p † | Sens @ 95% Spec | Spec @ 95% Sens |
| Diacetylspermine | 0.9 | 0.85–0.95 | <0.001 | 47.3 | 69 | 0.8 | 0.74–0.87 | <0.001 | 28.6 | 47.2 |
| Diacetylspermidine | 0.73 | 0.64–0.81 | <0.001 | 3.3 | 39.4 | 0.55 | 0.46–0.64 | 0.28 | 0 | 9.7 |
| Acetylspermidine | 0.77 | 0.69–0.84 | <0.001 | 29.7 | 23.9 | 0.53 | 0.44–0.62 | 0.5 | 16.5 | 0 |
| N3AP | 0.75 | 0.68–0.83 | <0.001 | 17.6 | 32.4 | 0.58 | 0.50–0.67 | 0.07 | 17.6 | 5.6 |
| Early Stage Serous Cases (n = 16) vs. Healthy Controls (n = 71) | Early Stage Serous Cases (n = 16) vs. Subjects with Benign Disease (n = 72) | |||||||||
| Metabolite | AUC | 95% CI | p † | Sens @ 95% Spec | Spec @ 95% Sens | AUC | 95% CI | p † | Sens @ 95% Spec | Spec @ 95% Sens |
| Diacetylspermine | 0.81 | 0.69–0.94 | <0.001 | 37.5 | 4.2 | 0.7 | 0.56–0.84 | 0.01 | 18.8 | 5.6 |
| Diacetylspermidine | 0.74 | 0.62–0.87 | 0.003 | 12.5 | 25.4 | 0.47 | 0.30–0.64 | 0.74 | 0 | 2.8 |
| Acetylspermidine | 0.66 | 0.49–0.83 | 0.049 | 31.3 | 4.2 | 0.54 | 0.34–0.75 | 0.58 | 31.3 | 0 |
| N3AP | 0.7 | 0.56–0.84 | 0.01 | 18.8 | 18.3 | 0.51 | 0.34–0.68 | 0.94 | 18.8 | 0 |
| Late Stage Serous Cases (n = 75) vs. Healthy Controls (n = 71) | Late Stage Serous Cases (n = 75) vs. Subjects with Benign Disease (n = 72) | |||||||||
| Metabolite | AUC | 95% CI | p † | Sens @ 95% Spec | Spec @ 95% Sens | AUC | 95% CI | p † | Sens @ 95% Spec | Spec @ 95% Sens |
| Diacetylspermine | 0.92 | 0.88–0.96 | <0.001 | 49.3 | 73.2 | 0.83 | 0.76–0.89 | <0.001 | 30.7 | 56.9 |
| Diacetylspermidine | 0.73 | 0.64–0.82 | <0.001 | 1.3 | 50.7 | 0.57 | 0.47–0.66 | 0.17 | 0 | 18.1 |
| Acetylspermidine | 0.79 | 0.72–0.87 | <0.001 | 29.3 | 38 | 0.55 | 0.45–0.64 | 0.33 | 16 | 2.8 |
| N3AP | 0.76 | 0.69–0.84 | <0.001 | 17.3 | 32.4 | 0.6 | 0.51–0.69 | 0.04 | 17.3 | 5.6 |
| Non-Serous Cases (n = 25) vs. Healthy Controls (n = 71) | Non-Serous Cases (n = 25) vs. Subjects with Benign Disease (n = 72) | |||||||||
| Metabolite | AUC | 95% CI | p † | Sens @ 95% Spec | Spec @ 95% Sens | AUC | 95% CI | p † | Sens @ 95% Spec | Spec @ 95% Sens |
| Diacetylspermine | 0.83 | 0.73–0.92 | <0.001 | 48 | 43.7 | 0.71 | 0.58–0.83 | 0.002 | 28 | 22.2 |
| Diacetylspermidine | 0.77 | 0.67–0.88 | <0.001 | 28,0 | 31 | 0.61 | 0.46–0.76 | 0.1 | 24 | 5.6 |
| Acetylspermidine | 0.72 | 0.59–0.85 | 0.001 | 28 | 5.6 | 0.53 | 0.37–0.68 | 0.71 | 20 | 0 |
| N3AP | 0.73 | 0.61–0.85 | <0.001 | 20 | 21.1 | 0.58 | 0.43–0.73 | 0.25 | 24 | 1.4 |
† Significance was determined by 2-sided Wilcoxon rank sum test.